Free cash flow
Neurocrine Biosciences Free cash flow decreased by 65.0% to $136.70M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 152.7%, from $54.10M to $136.70M. Over 4 years (FY 2021 to FY 2025), Free cash flow shows an upward trend with a 33.2% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase suggests improved operational efficiency or reduced capital intensity, providing more flexibility for capital allocation. A decrease may indicate higher investment in R&D or infrastructure, or potential challenges in converting earnings into cash.
Detailed definition
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and m...
Peer comparison
Large-cap medical device and pharmaceutical peers typically maintain strong, positive free cash flow, though levels vary based on the intensity of R&D spending and the lifecycle stage of major product lines.
free_cash_flowHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $98.90M | $56.10M | $0.00 | -$48.10M | $129.30M | $100.50M | $141.20M | -$133.70M | $172.80M | $204.40M | $118.10M | $119.10M | $53.00M | $149.90M | $235.20M | $54.10M | $89.50M | $214.30M | $390.80M | $136.70M |
| QoQ Change | — | -43.3% | -100.0% | — | +368.8% | -22.3% | +40.5% | -194.7% | +229.2% | +18.3% | -42.2% | +0.8% | -55.5% | +182.8% | +56.9% | -77.0% | +65.4% | +139.4% | +82.4% | -65.0% |
| YoY Change | — | — | — | — | +30.7% | +79.1% | — | -178.0% | +33.6% | +103.4% | -16.4% | +189.1% | -69.3% | -26.7% | +99.2% | -54.6% | +68.9% | +43.0% | +66.2% | +152.7% |
Free cash flow at Other Companies
Frequently Asked Questions
- What is Neurocrine Biosciences's free cash flow?
- Neurocrine Biosciences (NBIX) reported free cash flow of $136.70M in Q1 2026.
- How has Neurocrine Biosciences's free cash flow changed year-over-year?
- Neurocrine Biosciences's free cash flow increased by 152.7% year-over-year, from $54.10M to $136.70M.
- What is the long-term trend for Neurocrine Biosciences's free cash flow?
- Over 4 years (2021 to 2025), Neurocrine Biosciences's free cash flow has grown at a 33.2% compound annual growth rate (CAGR), from $237.80M to $748.70M.
- What does free cash flow mean?
- The cash remaining after a company pays for its operating expenses and capital investments.